The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow.

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Your doctor may recommend a triptan if nonsteroidal anti-inflammatory drugs (NSAIDs ... ketorolac (Toradol), an NSAID available as a nasal spray, to help manage migraine attacks that cause ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

A nasal spray of oxytocin significantly reduced acute ... levels of the hormone can contribute to a better mood and reduce anxiety by calming the brain’s fear center, the amygdala.

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

The nasal spray ... for the spray is esketamine, which is the “chemical cousin” of ketamine. Ketamine has been used by clinics across the U.S. to treat depression, anxiety and PTSD.

The Food and Drug Administration (FDA) approved Johnson & Johnson's ketamine-derived nasal spray to help millions of U.S. patients suffering from severe depression. Spravato, approved as a ...